GenVec, Inc. (GNVC) Continues Funding Streak from NIAID for HIV Vaccine Research
GenVec, Inc. (NASDAQ: GNVC) announced Thursday that it received a third year option of funding, as part of a five-year contract with the National Institute of Allergy and Infectious Disease. The company will receive up to $3.8 million to continue the development of new HIV vaccine candidates. GenVec’s research is based on its proprietary adenovirus vector and production cell line technologies. “We appreciate NIAID’s decision to execute its renewal option under our contract,” said Dr. Rick King, GenVec’s senior vice president of research and development. “GenVec’s adenovector technology platform now includes six distinct serotypes that can be used singly or…